PRTA— PROTHENA CORP PUBLIC LTD CO

MaterialsBiotechnology$477M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$9.7M-92.8%	$135.2M+47.9%	$91.4M+69.5%	$53.9M
Research and development	$134.9M-39.4%	$222.5M+0.9%	$220.6M+62.7%	$135.6M
General and administrative	$59.4M-11.6%	$67.2M+8.7%	$61.8M+23.9%	$49.9M
Restructuring costs	$30.1M	$0	$0	—
Total operating expenses	$224.3M-22.6%	$289.7M+2.6%	$282.4M+52.3%	$185.5M
Loss from operations	-$214.6M-38.9%	-$154.6M+19.1%	-$191.0M-45.2%	-$131.6M
Interest income	$14.1M-45.2%	$25.8M-16.8%	$31.0M+388.5%	$6.3M
Other expense, net	-$328K-77.3%	-$185K+59.6%	-$458K-15.4%	-$397K
Total other income, net	$13.8M-46.1%	$25.6M-16.1%	$30.6M+413.4%	$6.0M
Loss before provision for income taxes	-$200.8M-55.8%	-$128.9M+19.7%	-$160.5M-27.8%	-$125.6M
Provision for (benefit from) income taxes	$43.3M+753.5%	-$6.6M+50.8%	-$13.5M-55.4%	-$8.7M
Net loss	-$244.1M-99.6%	-$122.3M+16.8%	-$147.0M-25.7%	-$116.9M
Basic net loss per ordinary share (in USD per share)	-$4530.00-99.6%	-$2270.00+17.8%	-$2760.00-11.7%	-$2470.00
Diluted net loss per ordinary share (in USD per share)	-$4530.00-99.6%	-$2270.00+17.8%	-$2760.00-11.7%	-$2470.00
Shares used to compute basic net loss per share (in shares)	$53829000.00+0.1%	$53772000.00+1.0%	$53216000.00+12.3%	$47369000.00
Shares used to compute diluted net loss per share (in shares)	$53829000.00+0.1%	$53772000.00+1.0%	$53216000.00+12.3%	$47369000.00
Collaboration revenue
Revenue from license and intellectual property

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.